Show simple item record

dc.contributor.authorPilling, L
dc.contributor.authorTamosauskaite, J
dc.contributor.authorJones, G
dc.contributor.authorWood, A
dc.contributor.authorJones, L
dc.contributor.authorKuo, C-L
dc.contributor.authorKuchel, G
dc.contributor.authorFerrucci, L
dc.contributor.authorMelzer, D
dc.date.accessioned2019-01-28T15:23:00Z
dc.date.issued2019-01-16
dc.description.abstractObjective To compare prevalent and incident morbidity and mortality between those with the HFE p.C282Y genetic variant (responsible for most hereditary haemochromatosis type 1) and those with no p.C282Y mutations, in a large UK community sample of European descent. Design Cohort study. Setting 22 centres across England, Scotland, and Wales in UK Biobank (2006-10). Participants 451 243 volunteers of European descent aged 40 to 70 years, with a mean follow-up of seven years (maximum 9.4 years) through hospital inpatient diagnoses and death certification. Main outcome measure Odds ratios and Cox hazard ratios of disease rates between participants with and without the haemochromatosis mutations, adjusted for age, genotyping array type, and genetic principal components. The sexes were analysed separately as morbidity due to iron excess occurs later in women. Results Of 2890 participants homozygous for p.C282Y (0.6%, or 1 in 156), haemochromatosis was diagnosed in 21.7% (95% confidence interval 19.5% to 24.1%, 281/1294) of men and 9.8% (8.4% to 11.2%, 156/1596) of women by end of follow-up. p.C282Y homozygous men aged 40 to 70 had a higher prevalence of diagnosed haemochromatosis (odds ratio 411.1, 95% confidence interval 299.0 to 565.3, P<0.001), liver disease (4.30, 2.97 to 6.18, P<0.001), rheumatoid arthritis (2.23, 1.51 to 3.31, P<0.001), osteoarthritis (2.01, 1.71 to 2.36, P<0.001), and diabetes mellitus (1.53, 1.16 to 1.98, P=0.002), versus no p.C282Y mutations (n=175 539). During the seven year follow-up, 15.7% of homozygous men developed at least one incident associated condition versus 5.0% (P<0.001) with no p.C282Y mutations (women 10.1% v 3.4%, P<0.001). Haemochromatosis diagnoses were more common in p.C282Y/p.H63D heterozygotes, but excess morbidity was modest. Conclusions In a large community sample, HFE p.C282Y homozygosity was associated with substantial prevalent and incident clinically diagnosed morbidity in both men and women. As p.C282Y associated iron overload is preventable and treatable if intervention starts early, these findings justify re-examination of options for expanded early case ascertainment and screening.en_GB
dc.description.sponsorshipMedical Research Council (MRC)en_GB
dc.description.sponsorshipUniversity of Exeter Medical Schoolen_GB
dc.description.sponsorshipUniversity of Conneticut Health Centreen_GB
dc.description.sponsorshipNational Centre for Ageingen_GB
dc.description.sponsorshipPublic Health Englanden_GB
dc.identifier.citationVol 364, article k5222en_GB
dc.identifier.doi10.1136/bmj.k5222
dc.identifier.grantnumberMR/M023095/1en_GB
dc.identifier.grantnumberIntermural Research Programmeen_GB
dc.identifier.urihttp://hdl.handle.net/10871/35607
dc.language.isoenen_GB
dc.publisherBMJ Publishing Groupen_GB
dc.rightsThis is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.en_GB
dc.titleCommon conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobanken_GB
dc.typeArticleen_GB
dc.date.available2019-01-28T15:23:00Z
dc.identifier.issn0959-8138
dc.descriptionThis is the final published version. Available from BMJ publishing group via the DOI in this record.en_GB
dc.descriptionData are available on application to the UK Biobank (www.ukbiobank.ac.uk/register-apply).en_GB
dc.identifier.journalBMJen_GB
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2018-11-27
exeter.funder::Medical Research Council (MRC)en_GB
rioxxterms.funderEuropean Research Councilen_GB
rioxxterms.identifier.projectSZ-245 50371-GLUCOSEGENESFP7-IDEAS-ERCen_GB
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2018-11-27
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2019-01-28T15:18:23Z
refterms.versionFCDVoR
refterms.dateFOA2019-01-28T15:23:02Z
refterms.panelAen_GB
refterms.depositExceptionpublishedGoldOA
rioxxterms.funder.project04823660-607b-47f3-a4e7-a0cd0599d5b9en_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See:
http://creativecommons.org/licenses/by/4.0/.
Except where otherwise noted, this item's licence is described as This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.